Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlilumab + 6MHP Vaccine in Melanoma
NCT03617328Phase 2Completed
- Start
- Nov 2018
- Primary completion
- Jan 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of varlilumab in melanoma. Started Nov 2018; status: completed.
02
Drugs
varlilumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03617328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617328.